Roseola cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{Roseola}} | {{Roseola}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{DAMI}} | ||
==Overview== | ==Overview== | ||
| Line 10: | Line 10: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Neurology]] | |||
[[Category:Pediatrics]] | |||
[[Category:Dermatology]] | |||
Latest revision as of 00:02, 30 July 2020
|
Roseola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Roseola cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Roseola cost-effectiveness of therapy |
|
Risk calculators and risk factors for Roseola cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]